C54.9: Malignant neoplasm of corpus uteri, unspecified

C54.9, malignant neoplasm of corpus uteri, unspecified, is listed as a covered diagnosis in 8 Medicare billing and coding articles that apply to 60 HCPCS Level II codes, including C9726 (Placement and removal (if performed) of applicator into…), G0340 (Image-guided robotic linear accelerator-based stereotactic…), G0339 (Image-guided robotic linear accelerator-based stereotactic…). The articles come from 3 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with C54.9 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
C9726Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedureSpecial coverage instructions apply—1
G0340Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatmentCarrier judgment—1
G0339Image-guided robotic linear accelerator-based stereotactic radiosurgery, complete course of therapy in one session or first session of fractionated treatmentCarrier judgment—1
G0563Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance and real-time positron emissions-based delivery adjustments to 1 or more lesions, entire course not to exceed 5 fractionsCarrier judgment—1
Q0512Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day periodSpecial coverage instructions apply—2
Q0511Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day periodSpecial coverage instructions apply—2
Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mgCarrier judgment—1
Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mgCarrier judgment—1
Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mgCarrier judgment—1
Q5107Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mgSpecial coverage instructions apply—1
J9035Injection, bevacizumab, 10 mgCarrier judgment—1
J3590Unclassified biologicsCarrier judgment—1
C9257Injection, bevacizumab, 0.25 mgSpecial coverage instructions apply—1
Q5160Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mgCarrier judgment—1
J9267Injection, paclitaxel, 1 mgSpecial coverage instructions apply—1
J9264Injection, paclitaxel protein-bound particles, 1 mgCarrier judgment—1
J0461Injection, atropine sulfate, 0.01 mgSpecial coverage instructions apply—1
J0153Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)Special coverage instructions apply—1
J1250Injection, dobutamine hydrochloride, per 250 mgSpecial coverage instructions apply—1
J0280Injection, aminophyllin, up to 250 mgSpecial coverage instructions apply—1
J1245Injection, dipyridamole, per 10 mgSpecial coverage instructions apply—1
J8999Prescription drug, oral, chemotherapeutic, nosSpecial coverage instructions apply—1
J8530Cyclophosphamide; oral, 25 mgSpecial coverage instructions apply—1
J8597Antiemetic drug, oral, not otherwise specifiedSpecial coverage instructions apply—1
J8610Methotrexate; oral, 2.5 mgSpecial coverage instructions apply—1

35 more codes are listed. See every code with payment by region in Caduvo.

Medicare policy articles listing C54.9

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other C54 diagnoses (Malignant neoplasm of corpus uteri)

Frequently asked questions

Does Medicare cover C54.9 (Malignant neoplasm of corpus uteri, unspecified)?

Medicare covers items and services, not diagnoses. 8 Medicare billing and coding articles list C54.9 as a covered diagnosis for 60 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 C54.9?

The Level II codes from the policies most specific to this diagnosis are C9726 (Placement and removal (if performed) of applicator into…, 1 article); G0340 (Image-guided robotic linear accelerator-based stereotactic…, 1 article); G0339 (Image-guided robotic linear accelerator-based stereotactic…, 1 article); G0563 (Stereotactic body radiation therapy, treatment delivery…, 1 article); Q0512 (Pharmacy supply fee for oral anti-cancer, oral anti-emetic…, 2 articles). Code choice depends on the item supplied; check each code's descriptor.

Which Medicare policy articles list C54.9?

A56684 (Billing and Coding: Intraoperative Radiation Therapy); A56874 (Billing and Coding: Stereotactic Radiation Therapy: Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiation Therapy (SBRT)); A52370 (Billing and Coding: Bevacizumab and biosimilars), and 5 more articles.

What is ICD-10-CM code C54.9?

C54.9 is the ICD-10-CM code for malignant neoplasm of corpus uteri, unspecified, in category C54 (Malignant neoplasm of corpus uteri), chapter 2: Neoplasms.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 2: Neoplasms · All diagnoses · HCPCS lookup